Tanager Wealth Management LLP Has $500,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tanager Wealth Management LLP cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 941 shares of the medical research company’s stock after selling 251 shares during the period. Tanager Wealth Management LLP’s holdings in Thermo Fisher Scientific were worth $500,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. WCM Investment Management LLC grew its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after purchasing an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. grew its stake in shares of Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares during the last quarter. DMC Group LLC grew its stake in shares of Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after purchasing an additional 84 shares during the last quarter. S. R. Schill & Associates grew its stake in shares of Thermo Fisher Scientific by 106.3% in the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after purchasing an additional 792 shares during the last quarter. Finally, Check Capital Management Inc. CA bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $219,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the transaction, the chief executive officer now owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.6 %

Shares of TMO stock traded up $3.27 on Friday, reaching $544.79. 1,738,319 shares of the company were exchanged, compared to its average volume of 1,549,865. The company has a market cap of $207.95 billion, a price-to-earnings ratio of 35.21, a PEG ratio of 2.30 and a beta of 0.80. The company has a 50-day moving average of $571.39 and a 200-day moving average of $527.11. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the business posted $5.40 EPS. The firm’s revenue was down 4.9% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Analysts Set New Price Targets

Several brokerages recently weighed in on TMO. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. The Goldman Sachs Group upped their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $604.69.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.